The Pharma Data

NOVEMBER 29, 2020

HOOKIPA’s viral vectors target antigen presenting cells in vivo to activate the immune system. Both technologies enable repeat administration to augment and refresh immune responses. To expand its infectious disease portfolio, HOOKIPA entered into a collaboration and licensing agreement with Gilead Sciences, Inc.

Vaccine 52

Vaccine Clinical Trials Disease Therapies 52

Drug Target Review

FEBRUARY 28, 2024

gammadelta T cells link innate and adaptive immune responses. Chem Immunol Allergy 86:151-183 (2005). Normality sensing licenses local T cells for innate-like tissue surveillance. References Fichtner A, Ravens S, Prinz I. Human γδ TCR repertoires in health and disease. Cells 9(40):800 (2020). Holtmeier W, Kabelitz D.

Therapies 104

Therapies Engineering Molecular Biology Immune Response 104

The Pharma Data

NOVEMBER 9, 2020

Specifically, tezepelumab targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma. 2005; 172; 149–60. J Intern Med 2012;272:121–32.

Trials 52

Trials Production Clinical Trials Government 52

The Pharma Data

DECEMBER 21, 2020

Specifically, tezepelumab targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma. 2005; 172: 149-160. 2019;12(5):539-549.

Trials 40

Trials Production Clinical Trials Government 40